These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37583821)

  • 1. Synthesis and Evaluation of Bithiazole Derivatives As Potential α-Sarcoglycan Correctors.
    Ribaudo G; Carotti M; Ongaro A; Oselladore E; Scano M; Zagotto G; Sandonà D; Gianoncelli A
    ACS Med Chem Lett; 2023 Aug; 14(8):1049-1053. PubMed ID: 37583821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repairing folding-defective α-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D.
    Carotti M; Marsolier J; Soardi M; Bianchini E; Gomiero C; Fecchio C; Henriques SF; Betto R; Sacchetto R; Richard I; Sandonà D
    Hum Mol Genet; 2018 Mar; 27(6):969-984. PubMed ID: 29351619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bithiazole correctors rescue CFTR mutants by two different mechanisms.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2013 Aug; 52(31):5161-3. PubMed ID: 23865422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery.
    Carotti M; Scano M; Fancello I; Richard I; Risato G; Bensalah M; Soardi M; Sandonà D
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constrained bithiazoles: small molecule correctors of defective ΔF508-CFTR protein trafficking.
    Coffman KC; Nguyen HH; Phuan PW; Hudson BM; Yu GJ; Bagdasarian AL; Montgomery D; Lodewyk MW; Yang B; Yoo CL; Verkman AS; Tantillo DJ; Kurth MJ
    J Med Chem; 2014 Aug; 57(15):6729-38. PubMed ID: 25061695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
    Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.
    Ye L; Knapp JM; Sangwung P; Fettinger JC; Verkman AS; Kurth MJ
    J Med Chem; 2010 May; 53(9):3772-81. PubMed ID: 20373765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice.
    Davison HR; Taylor S; Drake C; Phuan PW; Derichs N; Yao C; Jones EF; Sutcliffe J; Verkman AS; Kurth MJ
    Bioconjug Chem; 2011 Dec; 22(12):2593-9. PubMed ID: 22034937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy.
    Yu GJ; Yoo CL; Yang B; Lodewyk MW; Meng L; El-Idreesy TT; Fettinger JC; Tantillo DJ; Verkman AS; Kurth MJ
    J Med Chem; 2008 Oct; 51(19):6044-54. PubMed ID: 18788728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
    Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
    Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS
    Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4'-Methyl-4,5'-bithiazole-based correctors of defective delta F508-CFTR cellular processing.
    Yoo CL; Yu GJ; Yang B; Robins LI; Verkman AS; Kurth MJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2610-4. PubMed ID: 18394886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.
    Donald MB; Rodriguez KX; Shay H; Phuan PW; Verkman AS; Kurth MJ
    Bioorg Med Chem; 2012 Sep; 20(17):5247-53. PubMed ID: 22841006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3.
    Scano M; Benetollo A; Nogara L; Bondì M; Dalla Barba F; Soardi M; Furlan S; Akyurek EE; Caccin P; Carotti M; Sacchetto R; Blaauw B; Sandonà D
    Hum Mol Genet; 2022 Feb; 31(4):499-509. PubMed ID: 34505136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
    Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis.
    van der Woerd WL; Wichers CG; Vestergaard AL; Andersen JP; Paulusma CC; Houwen RH; van de Graaf SF
    J Hepatol; 2016 Jun; 64(6):1339-47. PubMed ID: 26879107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Structure-activity Relationship of Aminoarylthiazole Derivatives as Potential Potentiators of the Chloride Transport Defect in Cystic Fibrosis.
    Liessi N; Pesce E; Salis A; Damonte G; Tasso B; Cichero E; Pedemonte N; Millo E
    Med Chem; 2021; 17(6):646-657. PubMed ID: 32141420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.